Howraman Meteran

Dr. Howraman Meteran

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
LTLouise Lindhardt Toennesen
Louise Lindhardt Toennesen
HMHowraman Meteran
Howraman Meteran
MHMorten Hostrup
Morten Hostrup
NGNina Rica Wium Geiker
Nina Rica Wium Geiker
CJCamilla Bjoern Jensen
Camilla Bjoern Jensen
VBVibeke Backer
Vibeke Backer

14 July 2022 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
CRCeline Lund-Nielsen Remvig
Celine Lund-Nielsen Remvig
CDCaroline Skovsgaard Diers
Caroline Skovsgaard Diers
HMHanieh Meteran
Hanieh Meteran
STSimon Francis Thomsen
Simon Francis Thomsen
TSTorben Sigsgaard
Torben Sigsgaard
HMHowraman Meteran
Howraman Meteran

1 August 2015 in Respiratory Medicine
Verified
Journal Article
Closed access
HMHowraman Meteran
Howraman Meteran
VBVibeke Backer
Vibeke Backer
KKKirsten Ohm Kyvik
Kirsten Ohm Kyvik
ASAxel Skytthe
Axel Skytthe
STSimon Francis Thomsen
Simon Francis Thomsen

3 June 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
PSPradeesh Sivapalan
Pradeesh Sivapalan
CUCharlotte Suppli Ulrik
Charlotte Suppli Ulrik
TLTherese Lapperre
Therese Lapperre
RBRasmus Dahlin Bojesen
Rasmus Dahlin Bojesen
JEJosefin Eklöf
Josefin Eklöf
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Background: Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also havingin vitroantiviral properties. This may improve outcomes in patients hospitalised for coronavirus disease 2019 (COVID-19).Methods: Placebo-controlled double-blind randomised multicentre trial. Patients aged ≥18 years, admitted to hospital for ≤48 h (not intensive care) with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription PCR test were recruited. The intervention was 500 mg daily azithromycin for 3 days followed by 250 mg daily azithromycin for 12 days combined with 200 mg twice-daily hydroxychloroquine for all 15 days. The control group received placebo/placebo. The primary outcome was days alive and discharged from hospital within 14 days (DAOH14).Results: After randomisation of 117 patients, at the first planned interim analysis, the data and safety monitoring board recommended stopping enrolment due to futility, based on pre-specified criteria. Consequently, the trial was terminated on 1 February 2021. 61 patients received the combined intervention and 56 patients received placebo. In the intervention group, patients had a median (interquartile range) 9.0 (3–11) DAOH14versus9.0 (7–10) DAOH14 in the placebo group (p=0.90). The primary safety outcome, death from all causes on day 30, occurred for one patient in the intervention groupversustwo patients receiving placebo (p=0.52), and readmittance or death within 30 days occurred for nine patients in the intervention groupversussix patients receiving placebo (p=0.57).Conclusions: The combination of azithromycin and hydroxychloroquine did not improve survival or length of hospitalisation in patients with COVID-19.

28 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
ANAmalie Ying Nielsen
Amalie Ying Nielsen
SHSimon Høj
Simon Høj
STSimon Francis Thomsen
Simon Francis Thomsen
HMHowraman Meteran
Howraman Meteran
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of children and 10% of adults worldwide. Current research suggests a correlation between serum vitamin D level and AD severity and that vitamin D supplementation could have a potential therapeutic effect on AD. Objectives: To conduct a systematic review and meta-analysis of studies of vitamin D supplementation for disease improvement in children and adults with AD. Methods: PubMed, EMBASE, and Cochrane were searched from 19 April to 20 April 2024. We included randomized controlled trials (RCTs) of patients with AD comparing an intervention group with a control group. The risk of bias of the selected studies was assessed using the Cochrane risk-of-bias tool for randomized trials. All analyses were conducted in R (v4.1.2; R Core Team 2021). Results: Eleven RCTs with 686 participants were included. The included trials had measured AD severity by using the SCOring Atopic Dermatitis (SCORAD) or the Eczema Area and Severity Index (EASI). Vitamin D supplementation significantly reduced AD severity compared with the control group (standardized mean difference = −0.41, 95% CI: −0.67 to −0.16, I2 = 58%, p < 0.01). Conclusions: Vitamin D supplementation reduces AD severity in children and adults. Larger-scale and longer-term studies are still needed to confirm this conclusion. This study has been registered on PROSPERO (CRD42024535014).

15 July 2022 in Journal of Asthma
Verified
Journal Article
Closed access
CDCaroline Skovsgaard Diers
Caroline Skovsgaard Diers
CRCeline Remvig
Celine Remvig
HMHanieh Meteran
Hanieh Meteran
STSimon Francis Thomsen
Simon Francis Thomsen
TSTorben Sigsgaard
Torben Sigsgaard
HMHowraman Meteran
Howraman Meteran
Patient education is a key element in the management of asthma.This study aimed to evaluate the popularity and usefulness of YouTube videos on asthma.Two authors screened and evaluated the 200 most...